University of California San Francisco | About UCSF | UCSF Benioff Children's Hospital San Francisco
Search Site | Find a Doctor

Jennifer Clarke, M.D.

Neuro-oncologist

Dr. Jennifer Clarke is a neuro-oncologist, or brain cancer specialist, at UCSF Medical Center. In particular, she is interested in recurring tumors and in tumors being treated with anti-angiogenic agents or substances designed to block the growth of blood vessels and inhibit tumor growth. In her research at the Brain Tumor Research Center at UCSF, she studies new imaging methods to diagnose tumors and to measure their response to treatment. She is also interested in quality of life issues for brain tumor patients and their caregivers.

Clarke earned a medical degree at the UCSF School of Medicine, completed a residency in neurology at UCSF and a fellowship in neuro-oncology at the Memorial Sloan-Kettering Cancer Center in New York. She is a member of the American Academy of Neurology, American Society of Clinical Oncology and Society for Neuro-Oncology. Clarke is an assistant professor of clinical neurology and neurological surgery at UCSF.

Clinics

Neuro-Oncology Clinic
400 Parnassus Ave., Eighth Floor
San Francisco, CA 94143
Phone: (415) 353-2966
Fax: (415) 353-2167

Hours: Monday to Friday
8 a.m. – 5 p.m.

Conditions & Treatments

More about Jennifer Clarke

Education

UCSF School of Medicine 2002

Residencies

UCSF Medical Center, Neurology 2006

Fellowships

Memorial Sloan-Kettering Cancer Center, Neuro-Oncology 2008

Selected Research and Publications

  1. Clarke JL. Bevacizumab and other targeted agents in the upfront treatment of glioblastoma. Semin Radiat Oncol. 2014 Oct; 24(4):273-8.
  2. Fogh S, Wahl M, Anwar M, Haas-Kogan D, Clarke JL, Sneed PK. Standardization and quality assurance of radiation therapy volumes for adults with high-grade gliomas. Semin Radiat Oncol. 2014 Oct; 24(4):259-64.
  3. Clarke JL, Molinaro AM, Phillips JJ, Butowski NA, Chang SM, Perry A, Costello JF, DeSilva AA, Rabbitt JE, Prados MD. A single-institution phase II trial of radiation, temozolomide, erlotinib, and bevacizumab for initial treatment of glioblastoma. Neuro Oncol. 2014 Jul; 16(7):984-90.
  4. Han SJ, Rolston JD, Molinaro AM, Clarke JL, Prados MD, Chang SM, Berger MS, DeSilva A, Butowski NA. Phase II trial of 7 days on/7 days off temozolmide for recurrent high-grade glioma. Neuro Oncol. 2014 Sep; 16(9):1255-62.
  5. Bloch O, Crane CA, Fuks Y, Kaur R, Aghi MK, Berger MS, Butowski NA, Chang SM, Clarke JL, McDermott MW, Prados MD, Sloan AE, Bruce JN, Parsa AT. Heat-shock protein peptide complex-96 vaccination for recurrent glioblastoma: a phase II, single-arm trial. Neuro Oncol. 2014 Jan; 16(2):274-9.
  6. Jafri NF, Clarke JL, Weinberg V, Barani IJ, Cha S. Relationship of glioblastoma multiforme to the subventricular zone is associated with survival. Neuro Oncol. 2013 Jan; 15(1):91-6.
  7. Nagpal S, Clarke JL. Neoplastic myelopathy. Semin Neurol. 2012 Apr; 32(2):137-45.
  8. Clarke JL. Leptomeningeal metastasis from systemic cancer. Continuum (Minneap Minn). 2012 Apr; 18(2):328-42.
  9. Clark AJ, Lamborn KR, Butowski NA, Chang SM, Prados MD, Clarke JL, McDermott MW, Parsa AT, Berger MS, Aghi MK. Neurosurgical management and prognosis of patients with glioblastoma that progresses during bevacizumab treatment. Neurosurgery. 2012 Feb; 70(2):361-70.
  10. Morris PG, Reiner AS, Szenberg OR, Clarke JL, Panageas KS, Perez HR, Kris MG, Chan TA, DeAngelis LM, Omuro AM. Leptomeningeal metastasis from non-small cell lung cancer: survival and the impact of whole brain radiotherapy. J Thorac Oncol. 2012 Feb; 7(2):382-5.
  11. Clarke JL, Deangelis LM. Primary central nervous system lymphoma. Handb Clin Neurol. 2012; 105:517-27.
  12. Clarke JL, Chang SM. Neuroimaging: diagnosis and response assessment in glioblastoma. Cancer J. 2012 Jan-Feb; 18(1):26-31.
  13. Polley MY, Lamborn KR, Chang SM, Butowski N, Clarke JL, Prados M. Conditional probability of survival in patients with newly diagnosed glioblastoma. J Clin Oncol. 2011 Nov 1; 29(31):4175-80.
  14. Grommes C, Oxnard GR, Kris MG, Miller VA, Pao W, Holodny AI, Clarke JL, Lassman AB. "Pulsatile" high-dose weekly erlotinib for CNS metastases from EGFR mutant non-small cell lung cancer. Neuro Oncol. 2011 Dec; 13(12):1364-9.
  15. Clarke JL, Ennis MM, Yung WK, Chang SM, Wen PY, Cloughesy TF, Deangelis LM, Robins HI, Lieberman FS, Fine HA, Abrey L, Gilbert MR, Mehta M, Kuhn JG, Aldape KD, Lamborn KR, Prados MD. Is surgery at progression a prognostic marker for improved 6-month progression-free survival or overall survival for patients with recurrent glioblastoma? Neuro Oncol. 2011 Oct; 13(10):1118-24.
  16. Clarke J, Butowski N, Chang S. Recent advances in therapy for glioblastoma. Arch Neurol. 2010 Mar; 67(3):279-83.
  17. Clarke JL, Pao W, Wu N, Miller VA, Lassman AB. High dose weekly erlotinib achieves therapeutic concentrations in CSF and is effective in leptomeningeal metastases from epidermal growth factor receptor mutant lung cancer. J Neurooncol. 2010 Sep; 99(2):283-6.
  18. Polley MY, Lamborn KR, Chang SM, Butowski N, Clarke JL, Prados M. Six-month progression-free survival as an alternative primary efficacy endpoint to overall survival in newly diagnosed glioblastoma patients receiving temozolomide. Neuro Oncol. 2010 Mar; 12(3):274-82.
  19. Clarke JL, Iwamoto FM, Sul J, Panageas K, Lassman AB, DeAngelis LM, Hormigo A, Nolan CP, Gavrilovic I, Karimi S, Abrey LE. Randomized phase II trial of chemoradiotherapy followed by either dose-dense or metronomic temozolomide for newly diagnosed glioblastoma. J Clin Oncol. 2009 Aug 10; 27(23):3861-7.
  20. Clarke JL, Chang S. Pseudoprogression and pseudoresponse: challenges in brain tumor imaging. Curr Neurol Neurosci Rep. 2009 May; 9(3):241-6.

Publications are derived from MEDLINE/PubMed and provided by UCSF Profiles, a service of the Clinical & Translational Science Institute (CTSI) at UCSF. Researchers can make corrections and additions to their publications by logging on to UCSF Profiles.